May 13th 2024
With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.
Biopharma’s Untapped Value: The Quest to Reverse First-Launch Failure Trends
December 8th 2022Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?
Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants
September 9th 2022Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
A Cross-Functional Formula: Operationalizing the Broader Role of Access
August 10th 2022The BCG Market Access Roundtable outlines the new and advanced access competencies required to enable functional operationalization and delivery of this critical role in biopharma—today a key strategic partner in achieving overall business goals.
The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition
August 10th 2022Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?